Intravenous Treatment and prophylaxis of haemorrhage
Adult: For bleeding due to hyperfibrinolysis: As 2% soln: Initially, 4-5 g over 1 hr, followed by continuous infusion at a rate of 1 g/hr for up to 8 hr or until bleeding has been controlled. Max: 24 g daily.
Oral Treatment and prophylaxis of haemorrhage
Adult: For bleeding due to hyperfibrinolysis: Initially, 4-5 g, followed by 1-1.25 g hrly for up to 8 hr or until bleeding has been controlled. Max: 24 g daily.
Oral Patients with haemophilia undergoing dental extraction
Adult: 50-100 mg/kg (up to 6 g) 4-6 hrly, started before the procedure up to a total of 7-10 days. Max: 24 hr daily.
Reduce dose if necessary.
May be taken with or without food. May be taken w/ meals to prevent GI upset.
Dilute w/ NaCl 0.9%, dextrose 5%, or Ringer’s inj.
Active intravascular clotting process, disseminated intravascular coagulation (w/o heparin). Concomitant use w/ factor IX complex and anti-inhibitor coagulant complex.
Patient w/ cardiac disease, haematuria of upper urinary tract, uraemia. Admin by rapid IV inj of undiluted soln. Hepatic and renal impairment. Pregnancy and lactation.
Monitor creatine phosphokinase (CPK) for signs of muscle damage esp in patients receiving long-term therapy. Monitor for fibrinogen, fibrin split products, BUN, and creatinine.
Symptoms: Transient hypotension, severe acute renal failure, seizures. Management: Haemodialysis or peritoneal dialysis may be beneficial.
Enhanced thrombogenic effect w/ oral tretinoin. May increase risk of thrombosis w/ fibrinogen concentrate. Potentially Fatal: May enhance risk of thrombosis w/ factor IX complex and anti-inhibitor coagulant complex.
May cause prolongation of template bleeding time at dosages >24 g daily.
Description: Aminocaproic acid is an antifibrinolytic used similarly to tranexamic acid. It inhibits fibrinolysis by competitively binding to plasminogen, blocking its binding to fibrin and the subsequent conversion to plasmin. Onset: Approx 1-72 hr. Pharmacokinetics: Absorption: Rapidly and completely absorbed from the GI tract. Bioavailability: 100% (oral). Time to peak plasma concentration: W/in 2 hr (oral). Distribution: Widely distributed through intravascular and extravascular compartments. Volume of distribution: 23 L (oral); 30 L (IV). Metabolism: Metabolised minimally in the liver. Excretion: Via urine (65% as unchanged drug, approx 11% as metabolites). Elimination half-life: 1-2 hr.
B02AA01 - aminocaproic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Aminocaproic Acid Injection, Solution (American Regent, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/09/2016.Aminocaproic Acid Solution and Tablet (Clover Pharmaceuticals Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/09/2016.Anon. Aminocaproic Acid. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/09/2016.Buckingham R (ed). Aminocaproic Acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/09/2016.McEvoy GK, Snow EK, Miller J et al (eds). Aminocaproic Acid. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/09/2016.